Cart
sales@molnova.com
WIN 51,708
CAS No. 144177-30-0
WIN 51,708( —— )
Catalog No. M34471 CAS No. 144177-30-0
WIN 51,708 is a neurokinin receptor (NK1) antagonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 414 | In Stock |
|
| 5MG | 686 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWIN 51,708
-
NoteResearch use only, not for human use.
-
Brief DescriptionWIN 51,708 is a neurokinin receptor (NK1) antagonist.
-
DescriptionWIN 51,708 is a neurokinin receptor (NK1) antagonist.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetNeurokinin Receptor
-
RecptorNeurokinin receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number144177-30-0
-
Formula Weight439.59
-
Molecular FormulaC29H33N3O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@@]12[C@@]3([C@]([C@]4([C@](C)(CC3)[C@@](C#C)(O)CC4)[H])(CC[C@]1(CC=5C(C2)=CN6C(N5)=NC=7C6=CC=CC7)[H])[H])[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Vofopitant dihydroch...
Vofopitant dihydrochloride (GR 205171A) is an orally available, selective tachykinin NK1 receptor antagonist that inhibits [3H]SP binding to NK1 with pKi values of 9.5 and 10.6, respectively.
-
Neurokinin A(4-10)
Neurokinin A (4-10) is a tachykinin NK2 receptor agonist. A structure-activity study of the neurokinin A (NKA) fragment NKA(4-10) was performed to investigate the importance of amino acid residues for receptor efficacy, potency and affinity at the NK2 receptor in human colon circular muscle.
-
[Lys5,MeLeu9,Nle10]-...
Highy selective and potent NK2 receptor agonist (IC50 = 6.1 nM). Induces contraction of the rat fundus and bladder (EC50 values are 117 and 10 nM respectively).
